Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 232

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

Open access
Kudo, Masatoshi, Matilla, Ana, Santoro, Armando, Melero, Ignacio, Gracián, Antonio Cubillo, Acosta-Rivera, Mirelis, Choo, Su-Pin, El-Khoueiry, Anthony B., Kuromatsu, Ryoko, El-Rayes, Bassel, Numata, Kazushi, Itoh, Yoshito, Di Costanzo, Francesco, Crysler, Oxana, Reig, Maria, Shen, Yun, Neely, Jaclyn, Tschaika, Marina, Wisniewski, Tami, Sangro, Bruno · 2021 · Journal of Hepatology

Abstract

BACKGROUND & AIMS: Patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B liver function are often excluded from clinical trials. In previous studies, overall survival for these patients treated with sorafenib was ∼3-5 months; thus, new treatments are needed. Nivolumab, alone or in combination with ipilimumab, is conditionally approved in the United States to treat patients with aHCC who previously received sorafenib. We describe nivolumab monotherapy outcomes in patients with Child-Pugh B status. METHODS: This phase I/II, open-label, non-comparative, multicentre trial (27 centres) included patients with Child-Pugh B (B7-B8) aHCC. Patients received intravenous nivolumab 240 mg every 2 weeks until unacceptable toxicity or disease progression. Primary endpoints were objective response rate (ORR) by investigator assessment (using Response Evaluation Criteria in Solid Tumors v1.1) and duration of response. Safety was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. RESULTS: Twenty-five sorafenib-naive and 24 sorafenib-treated patients began treatment between November 2016 and October 2017 (median follow-up, 16.3 months). Investigator-assessed ORR was 12% (95% CI 5-25%) with 6 patients responding; disease control rate was 55% (95% CI 40-69%). Median time to response was 2.7 months (interquartile range, 1.4-4.2), and median duration of response was 9.9 months (95% CI 9.7-9.9). Treatment-related adverse events (TRAEs) were reported in 25 patients (51%) and led to discontinuation in 2 patients (4%). The most frequent grade 3/4 TRAEs were hypertransaminasemia (n = 2), amylase increase (n = 2), and aspartate aminotransferase increase (n = 2). The safety of nivolumab was comparable to that in patients with Child-Pugh A aHCC. CONCLUSIONS: Nivolumab showed clinical activity and favourable safety with manageable toxicities, suggesting it could be suitable for patients with Child-Pugh B aHCC. LAY SUMMARY: In patients with advanced hepatocellular carcinoma, almost all systemic therapies require very good liver function, i.e. Child-Pugh A status. The evidence from this study suggests that nivolumab shows clinical activity and an acceptable safety profile in patients with hepatocellular carcinoma with Child-Pugh B status who have mild to moderate impairment of liver function or liver decompensation that might rule out other therapies. Further studies are warranted to assess the safety and efficacy of nivolumab in this patient population. CLINICAL TRIAL NUMBER: NCT01658878.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.04.047

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 232

Metadata

Authors
Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracián, A. C., Acosta-Rivera, M., Choo, S.-P., El-Khoueiry, A. B., Kuromatsu, R., El-Rayes, B., Numata, K., Itoh, Y., Di Costanzo, F., Crysler, O., Reig, M., Shen, Y., Neely, J., Tschaika, M., Wisniewski, T., & Sangro, B.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2021-09
Volume
75
Issue
3
Pages
600-609
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3165752903
Cited by
232
References
2
FWCI
19.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. https://app.cochat.ai/papers/10.1016/j.jhep.2021.04.047
The paper
Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracián, A. C., Acosta-Rivera, M., Choo, S.-P., El-Khoueiry, A. B., Kuromatsu, R., El-Rayes, B., Numata, K., Itoh, Y., Di Costanzo, F., Crysler, O., Reig, M., Shen, Y., Neely, J., Tschaika, M., Wisniewski, T., & Sangro, B. (2021). CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.04.047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.